1. Home
  2. CPAC vs ABUS Comparison

CPAC vs ABUS Comparison

Compare CPAC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cementos Pacasmayo S.A.A. (Each representing five)

CPAC

Cementos Pacasmayo S.A.A. (Each representing five)

HOLD

Current Price

$10.66

Market Cap

848.5M

Sector

Industrials

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.68

Market Cap

875.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPAC
ABUS
Founded
1949
2005
Country
Peru
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
848.5M
875.7M
IPO Year
2003
2008

Fundamental Metrics

Financial Performance
Metric
CPAC
ABUS
Price
$10.66
$4.68
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$12.90
$5.00
AVG Volume (30 Days)
55.2K
1.9M
Earning Date
04-27-2026
05-13-2026
Dividend Yield
5.24%
N/A
EPS Growth
N/A
55.26
EPS
N/A
N/A
Revenue
N/A
$14,083,000.00
Revenue This Year
$4.49
N/A
Revenue Next Year
N/A
$783.24
P/E Ratio
$19.78
N/A
Revenue Growth
N/A
128.21
52 Week Low
$5.20
$3.04
52 Week High
$11.50
$5.10

Technical Indicators

Market Signals
Indicator
CPAC
ABUS
Relative Strength Index (RSI) 55.46 59.30
Support Level $10.25 $4.19
Resistance Level $11.29 $4.71
Average True Range (ATR) 0.39 0.20
MACD 0.06 0.02
Stochastic Oscillator 84.72 89.52

Price Performance

Historical Comparison
CPAC
ABUS

About CPAC Cementos Pacasmayo S.A.A. (Each representing five)

Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: